fda warning letters compounded semaglutide october 2025 Medscape | The has approved once-daily oral 25 mg (Wegovy Pill, Novo Nordisk) as the first GLP-1 agonist pill for weight management. ⁠ Why the FDA Issued 30

Each time, the adaptation period tends to be slightly shorter and slightly less intense than the previous one, because the GLP-1 receptors are increasingly accustomed to agonist activity

Managing side effects

Chris Mertens, 35, of Menominee Falls, Wisconsin, said he had no trouble remembering to take the Wegovy pill every morning, which he did as part of a clinical trial in late 2022

Look for vendors who supply lyophilized powder with detailed certificates of analysis that confirm purity levels at or above 99%

In the REDEFINE 2 trial involving participants with type 2 diabetes, CagriSema significantly reduced HbA1c beyond what semaglutide alone achieved

Applicants are also required to work with their healthcare provider in the application process